Skip to main content

Fouad M. Hajjar, MD

Fouad M. Hajjar, MD

Medical Director of the Children's Center for Cancer and Blood Diseases, Chairman AdventHealth Institutional Review Board, Pediatric Oncologist

Cancer, Pediatrics

Fouad Hajjar

Overview

Dr. Fouad Hajjar, MD is board certified in pediatric hematology and oncology, and for nearly two decades has served as the co-director of the Children’s Center for Cancer & Blood Diseases. Dr. Hajjar was appointed to the Board of Governors of St. Jude Research Children’s Hospital in June of 2011. Dr. Hajjar is accompanied by a highly skilled and experienced team of doctors, specialists and support staff who handle a wide range of pediatric blood and cancer conditions, from leukemia and lymphoma to hemophilia, anemia and tumors. He earned his medical degree at St. Joseph’s University Medical School in Beirut, Lebanon. Dr. Hajjar went on to complete his residency at Buffalo Children’s Hospital, State University of New York at Buffalo, and his fellowship at Yale University School of Medicine in New Haven, Connecticut. Dr. Haijar is the Chairman of the Florida Hospital Institutional Review Board, the Central Florida Chapter of the Leukemia and Lymphoma Society and the Perinatal and Pediatric Ethic Committee.

Articles

Poorly differentiated, ovarian Sertoli-Leydig cell tumor with heterologous rhabdomyosarcoma and glandular elements: Diagnosis and management of a rare neoplasm

GYNECOLOGIC ONCOLOGY REPORTS

2018

PET-Guided Biopsy With Needle Navigation Facilitates Diagnosis of Angiosarcoma in Neurofibromatosis Type 1

PEDIATRIC BLOOD & CANCER

2013

Education & Training

Education

Saint Joseph University Medical School, Beirut, Lebanon

Residency

Buffalo Children’s Hospital, Buffalo, NY

Fellowship

Yale University School of Medicine, New Haven, CT

Specialty

Medical Oncology

Board Certifications

American Board of Pediatrics

Associated Clinical Trials

NCT00228696

National Wilms Tumor Late Effects Study

Icon for trial | 9442 National Wilms Tumor Late Effects Study

The purpose of this research is to learn more about the possible causes of Wilms tumor and the effects of successful treatment for Wilms tumor. You have been asked to participate in this voluntary study because you had a Wilms ...

NCT00904241

Neuroblastoma Biology Studies

Icon for trial | ANBL00B1 Neuroblastoma Biology Studies

This study is currently enrolling.

You are being asked to take part in this study because you have neuroblastoma. We would like to collect samples of your tumor, blood and/or bone marrow to learn more about neuroblastoma. We are asking your permission to use som ...

NCT00898365

Renal Tumors Classification, Biology, and Banking Study

Icon for trial | AREN03B2 Renal Tumors Classification, Biology, and Banking Study

This study is currently enrolling.

Over the past years, many studies have been done for children with kidney tumors. Each study done has increased what we know about these tumors and has helped doctors plan treatment for subjects with these tumors. Researchers n ...

NCT00736749

Umbrella Long-Term Follow-Up Protocol

Icon for trial | ALTE05N1 Umbrella Long-Term Follow-Up Protocol

This study is currently enrolling.

The overall goal of this study is to keep in contact with participants of COG clinical trials, so that up-to-date information will be available about these participants as they get older. This includes current name, contact, an ...

NCT03962543

A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients with Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) that are Progressing or Causing Significant Morbidity

Icon for trial | MEK-NF-201 A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients with Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) that are Progressing or Causing Significant Morbidity

This study is currently enrolling.

This research is conducted to study an investigational drug referred to as PD-0325901 (also known as mirdametinib) that has not been approved by the US Food and Drug Administration (FDA) or any other Regulatory Authority for th ...

NCT03914625

A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)

Icon for trial | AALL1731 A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B

This study is currently enrolling.

The overall goal of Part I of this study is to collect information about your leukemia and your response to the first phase of treatment, called Induction. Part I of the study is necessary to determine if you will be eligible f ...

NCT02567435

A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)

Icon for trial | ARST1431 A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma

This study is currently enrolling.

Subjects in Part 1 (Dose Finding Phase) Only: The overall goals of this study are: (1) to compare the effects, good and/or bad, of a new combination of chemotherapy using VAC/VI plus temsirolimus; (2) to find if adding the drug ...

NCT03959085

A Phase 3 Randomized Trial of INotuzumab Ozogamicin (IND#: 133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

Icon for trial | AALL1732 A Phase 3 Randomized Trial of INotuzumab Ozogamicin (IND#: 133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

This study is currently enrolling.

Disseminated B-Cell Lymphoblastic Lymphoma (B-LLy): The overall goal of this study is to determine the outcomes of subjects with disseminated B-LLy receiving High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL) therapy. Mix ...

NCT04166409

A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)

Icon for trial | ACNS1833 A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibr

This study is currently enrolling.

This study looks at how well a drug called selumetinib works when given to children and young adults with LGG. The study doctors want to see if selumetinib works as well as CV for getting rid of or shrinking LGGs and stopping t ...

NCT04293562

A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations.

Icon for trial | AAML1831 A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations.

This study is currently enrolling.

The overall goal of this study is to compare the effects, good and/or bad, of CPX-351 with daunorubicin and cytarabine on people with newly diagnosed AML to find out which is better. This study will compare standard chemotherap ...